Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, today announced that it has completed the acquisition of MedAlliance, a Switzerland-based developer of drug-eluting balloon technology. This acquisition adds a key growth driver to the company's coronary and peripheral vascular portfolios as we expect SELUTION SLR™ (Sustained Limus Release) Drug-Eluting Balloons (DEB) will be the first Sirolimus DEB to market in key geogr

Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (the "Company" or "Bausch Health") (NYSE/TSX:BHC), today announced it has completed its acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets. Under the terms of the agreement, Bausch + Lomb, through a

近日，康方生物（9926.HK）旗下子公司康方药业有限公司宣布，将携手荣昌生物制药（烟台）股份有限公司（688331.SH/09995.HK），推进康方生物独立自主研发的全球首款PD-1/CTLA-4双特异性抗体卡度尼利单抗注射液（商品名：开坦尼®）与荣昌生物自主开发的中国首款国产抗体偶联药物（ADC）注射用维迪西妥单抗（商品名：爱地希®）联合疗法的开发，并启动一项针对胃癌（含胃食管结合部腺癌）的II期临床研究。 开坦尼®是同时靶向PD-1和CTLA-4的人源化四价IgG1-ScFv对称结构的双特异性抗体，在肿瘤微环境中比在周围组织中对肿瘤浸润淋巴细胞具有更高的亲和力，采用Fc-null设计，在充分发挥抑制PD-1和CTLA-4两个免疫检查点的协同抗肿瘤作用的同时，相较两个靶点的单抗联合治疗具有更好的安全性。 开坦尼®已在多种实体瘤的临床试验中展现出优秀的抗肿瘤疗效。其中根据发布于2023美国临床肿瘤学会（ASCO）年会的两年随访数据，开坦尼®一线治疗晚期胃/胃食管结合部腺癌，全人群（无论PD-L1表达）缓解率高，长期生存获益突出。且研究结果显示，开坦尼®有望克服当下免疫治疗在PD-L

9月27日，荣昌生物宣布，将携手康方生物旗下子公司康方药业，推进康方生物独立自主研发的PD-1/CTLA-4双特异性抗体卡度尼利单抗注射液与荣昌生物自主开发的靶向HER2的抗体偶联药物（ADC）注射用维迪西妥单抗的联合疗法的开发，并启动一项针对胃癌（含胃食管结合部腺癌）的2期临床研究。 注射用维迪西妥单抗是以肿瘤表面的HER2蛋白为靶点的ADC产品，能精准识别和杀伤肿瘤细胞。该药目前已有胃癌、尿路上皮癌两大适应症获批上市。今年4月公布的2023版《中国临床肿瘤学会（CSCO）胃癌诊疗指南》显示，维迪西妥单抗作为HER2阳性（IHC3+或 2+）晚期胃癌三线治疗药物获得优先推荐，推荐等级由“Ⅱ级推荐”提升为“I级推荐”。 卡度尼利单抗注射液是同时靶向PD-1和CTLA-4的人源化四价IgG1-ScFv对称结构的双特异性抗体，在充分发挥抑制PD-1和CTLA-4两个免疫检查点的协同抗肿瘤作用的同时，相较两个靶点的单抗联合治疗具有更好的安全性。该药已经于2022年6月在中国获批，用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。 根据发布于2023美国临床肿瘤学会（ASCO）年会的

Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolon

Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for achieving the milestone. This follows the announcement of the first milestone achieved in the first discovery programme on May 4, 2023. Both programmes are pa

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs. The acquisition of Decibel builds on prior collaboration between the companies and includes three ongoing gene therapy programs targeting different forms of congenital, monogenic hearing loss. The most advanced clinical-stage candidate is DB-OTO, which is currently being studied in the glo

诺和诺德（Novo Nordisk）和Valo Health宣布，双方已达成一项总额达27亿美元的合作协议，将基于Valo的大型人类数据集和人工智能（AI）驱动的计算，发现和开发心脏代谢疾病的创新疗法。 两家公司之间的合作将利用Valo的Opal计算平台的功能，包括访问真实世界的患者数据、支持人工智能的小分子发现和Biowire人体组织建模平台，旨在加快发现和开发药物过程。 诺和诺德与Valo的合作将利用人类数据和遗传学的关键联合能力，以开发心脏代谢疾病的创新疗法。Valo可进行临床前新型药物靶点的识别与验证，以及针对这些靶点开发候选药物，并且可以帮助预测化合物的安全性和有效性。两家公司的合作除了包含靶标发现和验证外，诺和诺德与Valo还预计使用Opal计算平台发现和开发心血管疾病的三个临床前药物发现项目。 根据协议条款，Valo将获得一笔预付款和潜在的近期里程碑款项，总额为6000万美元，并有资格获得多达11个项目的里程碑付款，总额高达27亿美元，外加研发资金等费用。 这项协议标志着诺和诺德在心脏代谢领域上再度布局。诺和诺德上个月收购了加拿大生物技术公司Inversago Pharm

Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence Collaboration will apply Valo’s Opal Computational Platform™ and real-world patient dataset to enable the discovery and development of novel cardiometabolic drug programmes Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational Platform™ Val

2023年9月25日，默沙东在Clinicaltrials.gov网站上注册了MK-7240的三期临床。 MK-7240为一款TL1A抗体，由Prometheus Biosciences研发。2022年12月7日，Prometheus Biosciences公布PRA023治疗克罗恩病、溃疡性结肠炎两项二期临床的的最新数据，表明该产品有望成为首个以及最好的TL1A抗体。 PRA023为Prometheus的首发管线。 PRA023可能成为最好的TL1A抗体。 二期临床中，PRA023治疗溃疡性结肠炎，治疗组和对照组临床缓解率分别为26.5%和1.5%，内窥镜检查改善率分别为36.8%和6.0%，临床响应率分别为66.2%和22.4%。同时，治疗第一周就能起到症状控制的作用。 2023年4月16日，默沙东宣布以108亿美元的价格收购Prometheus Biosciences，加强在自身免疫病领域的布局。 此次注册的三期临床计划入组1020例中至重度溃疡性结肠炎患者，预计2029年完成。 总结 收购Prometheus，意味着默沙东将并购重心放在拓展自身免疫病领域的布局。TL1A抗体在炎